Sierra Oncology Company

Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Technology: Drug Design
Industry: Drug Discovery
Headquarters: Vancouver, British Columbia, Canada
Founded Date: 2004
Employees Number: 51-100
Funding Status: IPO

Visit Website
investors@sierraoncology.com
@sierraoncology
Register and Claim Ownership